Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
Summary
The purpose of the study is to understand whether study drugs domvanalimab and zimberelimab are safe and effective in combination with standard chemotherapy for patients with operable cancer of the esophagus, stomach, or gastroesophageal junction (where the stomach meets the esophagus). All participants will receive the study treatment. Participants will receive chemotherapy and two immune therapies drugs (domvanalimab and zimberelimab) for up to 4 months before surgery. After surgery and at least a 4 week recovery, participants will receive domvanalimab and zimberelimab for up to 8 months. After completion of the study treatment, participants will be followed for up to 5 years per standard of care.
Timeline
- Start
- 2026-02-01
- Primary completion
- 2026-12-01
- Completion
- 2029-12-01
Outcome
Outcome not reported
Stopped: “The pharmaceutical company is not moving forward with this intervention due to lack of efficacy.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Domvanalimab | Monoclonal antibody | 1600 mg | Intravenous |
| Subject | Zimberelimab | Monoclonal antibody | 480 mg | Intravenous |
| Background | Docetaxel | Small molecule | — | Intravenous |
| Background | Leucovorin | Small molecule | — | Intravenous |
| Background | Oxaliplatin | Small molecule | — | Intravenous |
| Background | fluorouracil | Small molecule | — | Intravenous |